TCL Archive New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years October 26, 2012
TCL Archive NeoRx Suspends Accrual, Treatment In Phase III trial Using STR For Myeloma. December 1, 2000